Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Axogen

Status and phase

Completed

Phase 4

Conditions

Cavernous Nerve Injury

Nerve Reconstruction

Radical Prostatectomy

Prostate Cancer

Peripheral Nerve Injury

Treatments

Other: Processed Human Nerve Tissue Scaffold

Study type

Interventional

Funder types

Industry

Identifiers

NCT00953277

ANG-CP-003

Details and patient eligibility

About

The purpose of this study is to determine if it is technically feasable to repair nerves that are injured as part of a planned surgical removal of the prostate and the surrounding tissue in subjects with prostate cancer. The study will also examine the long term outcomes on erectile function, continence and overall quality of life in the enrolled subjects.

Enrollment

12 patients

Sex

Male

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 years of age, but ≤70 years of age;
IIEF EF Domain*1 score ≥ 22;
be able to effectively communicate with study personnel;
be considered by the physician to be available for subsequent visits;
be willing to comply with all aspects of the treatment and evaluation schedule over a 24 month duration;
sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures; and
require radical prostatectomy.

Exclusion criteria

prior surgery in the last 6 months which could affect sexual function;
history of Peyronie's disease;
significant neurological disorder (i.e. multiple sclerosis, peripheral neuropathy);
treatment for major psychiatric disorders;
history of penile implant or prosthesis;
history of diabetic neuropathy;
life expectancy of less than two years;
concurrently involved in another investigational study;
uncontrolled hypertension with systolic BP >200mmHg or diastolic BP >115mmHg is present at screening;
currently receiving or planned treatment with chemotherapy or radiation therapy;
diagnosis of bony metastasis;
known allergy or severe intolerance to PDE-5 inhibitors; or
cardiac pacing equipment or other electro-mechanical devices which preclude the use of CaverMap™ neurostimulator.